| 周雯欣,郭昭廷,胡明,杨男,杨舒,周乃彤.地黄叶总苷胶囊联用厄贝沙坦片治疗慢性肾小球肾炎的药物经济学评价[J].中国药事,2023,(6):726-734 |
| 地黄叶总苷胶囊联用厄贝沙坦片治疗慢性肾小球肾炎的药物经济学评价 |
| Pharmacoeconomic Evaluation of Rehmanniaglutinosa Leaf Total Glycosides Capsule Combined with Irbesartan Tablets in the Treatment of Chronic Glomerulonephritis |
| 投稿时间：2022-11-07 |
| DOI：10.16153/j.1002-7777.2023.06.013 |
| 中文关键词: 地黄叶总苷胶囊 成本-效用分析 马尔可夫模型 慢性肾小球肾炎 药物经济学 |
| 英文关键词: rehmanniaglutinosa leaf total glycosides capsule cost utility analysis markov model chronic glomerulonephritis pharmacoeconomics |
| 基金项目: |
|
| 摘要点击次数: 546 |
| 全文下载次数: 369 |
| 中文摘要: |
| 目的：从全社会角度出发，评价地黄叶总苷胶囊联用厄贝沙坦片治疗慢性肾小球肾炎的经济性。方法：基于一项随机、对照、多中心临床试验研究，构建决策树-Markov模型，以质量调整生命年 （QALY）为产出指标，以2020年3倍人均GDP作为意愿支付阈值，计算增量成本效用比，并对关键指标进行单因素和概率敏感性分析，评价地黄叶总苷胶囊联用厄贝沙坦片对比单用厄贝沙坦片治疗慢性肾小球肾炎的长期经济性。结果：地黄叶总苷胶囊联用厄贝沙坦片与单用厄贝沙坦片比较的ICUR值为 84871.48元/QALY，小于2020年我国3倍人均GDP。单因素敏感性分析结果显示，各参数在一定范围内变化后，联用方案仍具有经济性。概率敏感性分析显示，当意愿支付阈值为3倍人均GDP时，联用方案的可接受概率远高于化学药单用，表明基线分析结果稳健。结论：对于慢性肾小球肾炎的治疗，地黄叶总苷胶囊联用厄贝沙坦片相比于单用厄贝沙坦片具有长期经济学优势。 |
| 英文摘要: |
| Objective: To evaluate the cost-effectiveness of Rehmanniaglutinosa leaf total glycosides capsule combined with irbesartan tablets in the treatment of chronic glomerulonephritis from the perspective of the whole society. Methods: Based on a randomized, controlled, multi-center clinical trial study, a decisiontree-Markov model was constructed. The quality adjusted life year (QALY) was taken as the output indicator, and three times gross domestic product (GDP) per capita in 2020 was taken as the threshold of willingness to pay. The incremental cost utility ratio was calculated, and the single factor and probability sensitivity analysis were performed for key indicators. To evaluate the long-term economics of Rehmanniaglutinosa leaf total glycosides capsule combined with irbesartan tablets compared with irbesartan tablets alone in the treatment of chronic glomerulonephritis. Results: Compared with irbesartan tablets alone, the ICUR value of Rehmanniaglutinosa leaf total glycosides capsule combined with irbesartan tablets was 84871.48 yuan/QALY, which was less than 3 times of China's per capita GDP in 2020. The results of single factor sensitivity analysis showed that the combined scheme wasstill economical after the parameters changed within a certain range. The probability sensitivity analysis showed that when the willingness to pay threshold was 3 times the per capita GDP, the acceptable probability of the combined scheme wasmuch higher than that of the single use of chemical drug, indicating that the baseline analysis results were robust. Conclusion: For the treatment of chronic glomerulonephritis, Rehmanniaglutinosa leaf total glycosides capsule combined with irbesartan tablets has long-term economic advantages compared with the single use of irbesartan tablets. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|